NYSE$XRN
Global Medical REIT Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Global Medical REIT reported its financial results for the fourth quarter and full year ended December 31, 2024, highlighting increased rental revenue and strategic acquisitions, alongside a joint venture with Heitman.
Global Medical REIT experienced a 6.1% year-over-year increase in rental revenue for Q4 2024, reaching $35.0 million, primarily driven by recent acquisitions. Despite this, net income attributable to common stockholders was $1.4 million, or $0.02 per diluted share, impacted by one-time severance costs and an impairment charge. The company also announced a joint venture with Heitman and provided 2025 AFFO guidance.
- Rental revenue for the fourth quarter of 2024 increased by 6.1% year-over-year to $35.0 million, driven by acquisitions.
- Net income attributable to common stockholders for Q4 2024 was $1.4 million ($0.02 per diluted share), compared to a net loss of $0.8 million ($0.01 per diluted share) in the prior year period.
- The company completed the acquisition of 10 properties from a 15-property portfolio for $49.5 million and entered into a joint venture with Heitman, selling two assets for $35.2 million.
- FFO attributable to common stockholders and noncontrolling interest was $11.1 million ($0.15 per share and unit), and AFFO was $15.8 million ($0.22 per share and unit) for Q4 2024.
Headline financials
Revenue & EPS history
Global Medical REIT · Revenue · Quarterly
$35.2M
Forward guidance
Global Medical REIT is introducing full year 2025 AFFO per share and unit guidance of $0.89 to $0.93, based on assumptions including no additional acquisitions or dispositions beyond announced activity and no further equity or debt issuances other than normal course Revolver borrowing/repayments.
Tailwinds
- Guidance range of $0.89 to $0.93 AFFO per share and unit for full year 2025.
- Expects to complete the acquisition of the remaining two properties from the five-property portfolio during Q2 2025.
- New 15-year triple-net lease with CHRISTUS Health for the Beaumont, Texas facility, with rent commencing in Q2 2025.
- Joint venture with Heitman is expected to provide additional opportunities to acquire assets and earn ancillary fee income.
- The company's disciplined acquisition approach for quality healthcare real estate is expected to continue.
Headwinds
- Guidance assumes no additional acquisitions or dispositions beyond what has been completed or announced.
- Guidance assumes no additional equity or debt issuances other than normal course Revolver borrowing/repayments.
- AFFO guidance excludes one-time obligations related to the CEO succession plan.
- The Company's 2025 guidance is subject to change and actual results may differ materially from expectations.
- Prospect Medical Group, representing 0.8% of total annualized base rent, filed for Chapter 11 bankruptcy, with no decision yet on accepting or rejecting its three leases.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+0.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.1%
Avg return
30 days after
56%
22 / 39 earnings
Positive
+7.3%
Q4 2016
Best reaction
-9.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.2% | -4.2% | — | |
| Q4 2025 | -1.6% | -2.6% | -13.2% | |
| Q3 2025 | +1.8% | +3.2% | +1.7% | |
| Q1 2025 | -9.8% | -11.7% | -17.0% | |
| Q4 2024 | +3.8% | +4.4% | +3.1% | |
| Q3 2024 | -2.6% | -3.6% | -7.4% | |
| Q2 2024 | -1.8% | -0.3% | +1.0% | |
| Q1 2024 | +3.4% | +4.8% | +8.4% | |
| Q4 2023 | -5.6% | -2.7% | -5.7% | |
| Q3 2023 | -1.8% | -0.8% | +11.7% | |
| Q2 2023 | +3.5% | +4.8% | -1.5% | |
| Q1 2023 | +0.8% | +1.8% | +1.9% | |
| Q4 2022 | -4.0% | -1.2% | -13.0% | |
| Q3 2022 | -0.9% | +0.2% | +12.3% | |
| Q2 2022 | -0.5% | -1.3% | -11.0% | |
| Q1 2022 | -5.3% | -11.9% | -12.5% | |
| Q4 2021 | -3.2% | -2.2% | +1.9% | |
| Q3 2021 | +1.6% | +1.0% | -2.5% | |
| Q2 2021 | -0.7% | -0.2% | +3.7% | |
| Q1 2021 | -1.2% | +1.0% | +5.2% | |
| Q4 2020 | +1.6% | +3.9% | +0.2% | |
| Q3 2020 | +2.0% | +1.4% | +7.2% | |
| Q2 2020 | +4.8% | +11.4% | +11.6% | |
| Q1 2020 | +7.0% | +9.3% | +26.0% | |
| Q4 2019 | +4.7% | -7.2% | -41.1% | |
| Q3 2019 | +2.3% | +9.5% | +22.4% | |
| Q2 2019 | -0.7% | +1.8% | +5.0% | |
| Q1 2019 | +1.4% | +4.5% | +7.1% | |
| Q4 2018 | +0.8% | +2.6% | -2.0% | |
| Q3 2018 | +2.2% | +2.0% | +6.4% | |
| Q2 2018 | +4.3% | +6.7% | +12.2% | |
| Q1 2018 | +2.6% | -0.1% | +4.6% | |
| Q4 2017 | +5.8% | +6.3% | +3.9% | |
| Q3 2017 | +3.1% | +3.7% | -2.8% | |
| Q2 2017 | +0.7% | +2.8% | +2.8% | |
| Q1 2017 | -1.2% | +0.0% | +0.3% | |
| Q4 2016 | +7.3% | +9.3% | +17.1% | |
| Q3 2016 | -8.5% | -14.9% | -0.2% | |
| Q2 2016 | +1.1% | +2.3% | -5.0% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro